


**AMENDMENTS TO THE CLAIMS**

Please amend claims 3, 4, 5, 6, 11, 12, and 13 as follows:

1. **(Canceled)**

2. **(Canceled)**

3. **(Previously Presented)** An anti-inflammatory compound comprising the following structure:



wherein

$X_a$  is a membrane translocation domain comprising from 6 to 15 amino acid residues;

$X_1$  is L, A, I or nor-leucine (Nle);

$X_2$  is D, E, N, Q, homoserine (Hser) or 2-ketopropylalanine (2-ketopropyl-A);

$X_3$  is W, F Y, 4-biphenyl-alanine (Bpa), homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), or cyclohexyl-alanine (Cha);


$X_4$  is S, A, E, L, T, nor-leucine (Nle), or homoserine (Hser);

$X_5$  is W, H, homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), O-benzyl serine (SeroBn), or 3-Pyridylalanine (3-Pal); and

$X_6$  is L, A, I, or nor-leucine (Nle),

wherein the anti-inflammatory compound is less than 100 amino acids in length.

4. **(Currently Amended)** The anti-inflammatory compound of claim 3, wherein  $X_a$  is the amino acid sequence TA **An anti-inflammatory compound comprising the following structure:**



wherein

$X_a$  is Thr-Ala;

$X_1$  is L, A, I or nor-leucine (Nle);

$X_2$  is D, E, N, Q, homoserine (Hser) or 2-ketopropylalanine (2-ketopropyl-A);

$X_3$  is W, F Y, 4-biphenyl-alanine (Bpa), homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), or cyclohexyl-alanine (Cha);

$X_4$  is S, A, E, L, T, nor-leucine (Nle), or homoserine (Hser);

X<sub>5</sub> is W, H, homophenylalanine (Hphe), 2-Naphthylalanine (2-Nal), 1-Naphthylalanine (1-Nal), O-benzyl serine (SeroBn), or 3-Pyridylalanine (3-Pal); and

X<sub>6</sub> is L, A, I, or nor-leucine (Nle),

wherein the anti-inflammatory compound is less than 100 amino acids in length.

5. (Currently Amended) The anti-inflammatory compound of claim 3, further comprising the variable X<sub>7</sub> immediately C-terminal to X<sub>6</sub>, wherein X<sub>7</sub> is the amino acid sequence QTE.

6. (Currently Amended) The anti-inflammatory compound of claim 3, wherein said compound comprises a sequence selected from the group consisting of Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu TALDWSWLQTE (SEQ ID NO:28), Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu LDWSWLQTE (SEQ ID NO:29), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu TALDWSWL (SEQ ID NO:30), Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ALDWSWLQTE (SEQ ID NO:31), Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu LDWSWLQTE (SEQ ID NO:32), Leu-Asp-Trp-Ser-Trp-Leu LDWSWL (SEQ ID NO:33), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr TALDWSWLQQT (SEQ ID NO:34), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln TALDWSWLQ (SEQ ID NO:35), Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr ALDWSWLQQT (SEQ ID NO:36), Leu-Asp-Trp-Ser-Trp-Leu-Gln LDWSWLQ (SEQ ID NO:37), Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr LDWSWLQQT (SEQ ID NO:38), Ala-Asp-Trp-Ser-Trp-Leu ADWSWL (SEQ ID NO:39), Leu-Asp-Trp-Ser-Trp-Ala LDWSWA (SEQ ID NO:40), Ala-Asp-Trp-Ser-Trp-Ala ADWSWA (SEQ ID NO:41), Leu-Asp-Phe-Ser-Trp-Leu LDPSWL (SEQ ID NO:42), Leu-Asp-Tyr-Ser-Trp-Leu LDYSWL (SEQ ID NO:43), Leu-Asp-Trp-Ala-Trp-Leu LDWAWL (SEQ ID NO:44), Leu-Asp-Trp-Glu-Trp-Leu LDWEWL (SEQ ID NO:45), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu TAADWSWLQTE (SEQ ID NO:46), Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ADWSWLQTE (SEQ ID NO:47), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Leu TAADWSWL (SEQ ID NO:48), Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu AADWSWLQTE (SEQ ID NO:49), Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ADWSWLQTE (SEQ ID NO:50), Ala-Asp-Trp-Ser-Trp-Leu ADWSWL (SEQ ID NO:51), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr TAADWSWLQQT (SEQ ID NO:52), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln TAADWSWLQ (SEQ ID NO:53), Ala-Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr AADWSWLQFT (SEQ ID NO:54), Ala-Asp-Trp-Ser-Trp-Leu-Gln ADWSWLQ (SEQ ID NO:55), Ala-Asp-Trp-Ser-Trp-Leu-Gln-Thr ADWSWLQFT (SEQ ID NO:56), Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu ALDWSWAQTE (SEQ ID NO:57), Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu LDWSWAQTE (SEQ ID NO:58), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Ala TALDWSWA (SEQ ID NO:59), Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu ALDWSWAQTE (SEQ ID NO:60), Leu-

Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu LDWSWAQTE (SEQ ID NO:61), Leu-Asp-Trp-Ser-Trp-Ala LDWSWA (SEQ ID NO:62), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr TALDWSWAQT (SEQ ID NO:63), Thr-Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln TALDWSWAQ (SEQ ID NO:64) , Ala-Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr ALDWSWAQT (SEQ ID NO:65), Leu-Asp-Trp-Ser-Trp-Ala-Gln LDWSWAQ (SEQ ID NO:66), Leu-Asp-Trp-Ser-Trp-Ala-Gln-Thr LDWSWAQT (SEQ ID NO:67), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu TAADWSWAQTE (SEQ ID NO:68), Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu ADWSWAQTE (SEQ ID NO:69), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Ala TAADWSWA (SEQ ID NO:70), Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu AADWSWAQTE (SEQ ID NO:71), Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr-Glu ADWSWAQTE (SEQ ID NO:72), Ala-Asp-Trp-Ser-Trp-Ala ADWSWA (SEQ ID NO:73), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr TAADWSWAQT (SEQ ID NO:74), Thr-Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln TAADWSWAQ (SEQ ID NO:75), Ala-Ala-Asp-Trp-Ser-Trp-Ala-Gln AADWSWAQ (SEQ ID NO:76), Ala-Asp-Trp-Ser-Trp-Ala-Gln ADWSWAQ (SEQ ID NO:77), Ala-Asp-Trp-Ser-Trp-Ala-Gln-Thr ADWSWAQT (SEQ ID NO:78), Thr-Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr-Glu TALDFSWLQTE (SEQ ID NO:79), Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr-Glu LDWSWLQTE (SEQ ID NO:80), Thr-Ala-Leu-Asp-Phe-Ser-Trp-Leu TALDFSWL (SEQ ID NO:81), Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr-Glu ALDWSWLQTE (SEQ ID NO:82), Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr-Glu LDWSWLQTE (SEQ ID NO:83), Leu-Asp-Phe-Ser-Trp-Leu LDWSWL (SEQ ID NO:84), Thr-Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr TALDFSWLQT (SEQ ID NO:85), Thr-Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln TALDFSWLQ (SEQ ID NO:86), Ala-Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr ALDWSWLQT (SEQ ID NO:87), Leu-Asp-Phe-Ser-Trp-Leu-Gln LDWSWLQ (SEQ ID NO:88), Leu-Asp-Phe-Ser-Trp-Leu-Gln-Thr LDWSWLQT (SEQ ID NO:89), Thr-Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr Gln-Thr Glu TALDYSWLQTE (SEQ ID NO:90) , Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr Glu LDYSWLQTE (SEQ ID NO:91), Thr-Ala-Leu-Asp-Tyr-Ser-Trp-Leu TALDYSWL (SEQ ID NO:92), Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr-Glu ALDYSWLQTE (SEQ ID NO:93), Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr-Glu LDYSWLQTE (SEQ ID NO:94), Leu-Asp-Tyr-Ser-Trp-Leu LDYSWL (SEQ ID NO:95), Thr-Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr Gln-Thr Glu TALDYSWLQT (SEQ ID NO:96), Thr-Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln TALDYSWLQ (SEQ ID NO:97), Ala-Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr ALDYSWLQT (SEQ ID NO:98), Leu-Asp-Tyr-Ser-Trp-Leu-Gln LDYSWLQ (SEQ ID NO:99), Leu-Asp-Tyr-Ser-Trp-Leu-Gln-Thr LDYSWLQT (SEQ ID NO:100), Thr-Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr-Glu TALDWAWLQTE (SEQ ID NO:101), Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr-Glu LDWAWLQTE (SEQ ID NO:102) , Thr-Ala-Leu-Asp-Trp-Ala-Trp-Leu TALDWAWL (SEQ ID NO:103), Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr-Glu ALDWAWLQTE (SEQ ID NO:104), Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr-Glu LDWAWLQTE (SEQ ID NO:105) , Leu-

Asp-Trp-Ala-Trp-Leu LDWAWL(SEQ ID NO:106), Thr-Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln  
Thr TALDWAWLQT(SEQ ID NO:107), Thr-Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln  
TALDWAWLQ(SEQ ID NO:108), Ala-Leu-Asp-Trp-Ala-Trp-Leu-Gln-Thr ALDWAWLQT  
(SEQ ID NO:109), Leu-Asp-Trp-Ala-Trp-Leu-Gln LDWAWLQ(SEQ ID NO:110), Leu-Asp-  
Trp-Ala-Trp-Leu-Gln-Thr LDWAWLQT(SEQ ID NO:111), Thr-Ala-Leu-Asp-Trp-Glu-Trp-  
Leu-Gln-Thr-Glu TALDWEWLQTE(SEQ ID NO:112), Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr  
Glu LDWEWLQTE(SEQ ID NO:113), Thr-Ala-Leu-Asp-Trp-Glu-Trp-Leu TALDWEWL  
(SEQ ID NO:114), Ala-Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr-Glu ALDWEWLQTE(SEQ ID  
NO:115), Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr-Glu LDWEWLQTE(SEQ ID NO:116), Leu-  
Asp-Trp-Glu-Trp-Leu LDWEWL(SEQ ID NO:117), Thr-Ala-Leu-Asp-Trp-Glu-Trp-Leu-Gln-  
Thr TALDWEWLQT(SEQ ID NO:118), Thr-Ala-Leu-Asp-Trp-Glu-Trp-Leu-Gln  
TALDWEWLQ(SEQ ID NO:119), Ala-Leu-Asp-Trp-Glu-Trp-Leu-Gln-Thr ALDWEWLQT  
(SEQ ID NO:120), Leu-Asp-Trp-Glu-Trp-Leu-Gln LDWEWLQ(SEQ ID NO:121), and Leu-  
Asp-Trp-Glu-Trp-Leu-Gln-Thr LDWEWLQT(SEQ ID NO:122).

**7. (Previously Presented)** The anti-inflammatory compound of claim 3, wherein X<sub>a</sub> consists of 6-12 amino acid residues.

**8. (Previously Presented)** The anti-inflammatory compound of claim 3, wherein X<sub>a</sub> consists of 6-10 amino acid residues.

**9. (Previously Presented)** The anti-inflammatory compound of claim 3, wherein X<sub>a</sub> comprises at least five basic amino acid residues.

**10. (Previously Presented)** The anti-inflammatory compound of claim 7, wherein X<sub>a</sub> comprises at least five amino acid residues independently selected from L-Arginine, D-Arginine, L-Lysine and D-Lysine.

**11. (Currently Amended)** The anti-inflammatory compound of claim 3, wherein X<sub>a</sub> is selected from the group consisting of Arg-Arg-Met-Lys-Trp-Lys-Lys RRMKWKK (SEQ ID NO:123), Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg YGRKKRRQRRR (SEQ ID NO:124), D-Tyr-D-Gly-D-Arg-D-Lys-D-Lys-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Arg ygrkkrrqrrr (SEQ ID NO:125), Tyr-Ala-Arg-Lys-Ala-Arg-Arg-Gln-Ala-Arg-Arg YARKARRQARR (SEQ ID NO:126), D-Tyr-D-Ala-D-Arg-D-Lys-D-Ala-D-Arg-D-Arg-D-Gln-D-Ala-D-Arg-D-Arg yarkarrqarr (SEQ ID NO:127), Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg YARAARRAARR (SEQ ID NO:128), D-Tyr-D-Ala-D-Arg-D-Ala-D-Ala-D-Arg-D-Gln-D-Ala-D-Arg-D-Arg yaraarrarrr (SEQ ID NO:129).

D-Arg-D-Ala-D-Ala-D-Arg-D-Arg yaraarraarr (SEQ ID NO:129), D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys rrrkwwkk (SEQ ID NO:130), Arg-Arg-Arg-Arg-Arg-Arg RRRRRR (SEQ ID NO:149), Arg-Arg-Arg-Arg-Arg-Arg RRRRRRR (SEQ ID NO:150), Arg-Arg-Arg-Arg-Arg-Arg RRRRRRRR (SEQ ID NO:151), Arg-Arg-Arg-Arg-Arg-Arg-Arg Arg-Arg RRRRRRRRR (SEQ ID NO:152), Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg RRRRRRRRR (SEQ ID NO:153), Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg RRRRRRRRR (SEQ ID NO:154), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg D-Arg rrrrrr (SEQ ID NO:155), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg rrrrrr (SEQ ID NO:156), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg rrrrrr (SEQ ID NO:157), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg rrrrrr (SEQ ID NO:158), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg rrrrrr (SEQ ID NO:159), and D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg rrrrrr (SEQ ID NO:160).

12. **(Currently Amended)** An anti-inflammatory compound comprising an amino acid sequence selected from the group consisting of Arg-Arg-Met-Lys-Trp-Lys-Lys-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu RRMKWKKTALDWSWLQTE (SEQ ID NO:131), D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-Lys-D-Lys-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu rrrkwwkkTALDWSWLQTE (SEQ ID NO:132), Tyr-Gly-Arg-Lys-Lys-Arg-Gln-Arg-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu YGRKKRRQRRRTALDWSWLQTE (SEQ ID NO:133), D-Tyr-D-Gly-D-Arg-D-Lys-D-Lys-D-Arg-D-Gln-D-Arg-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu ygrkkrrqrrrTALDWSWLQTE (SEQ ID NO:134), D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu rrrrrrrrTALDWSWLQTE (SEQ ID NO:135), Arg-Arg-Arg-Arg-Arg-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu YARKARRQARRTALDWSWLQTE (SEQ ID NO:136), Tyr-Ala-Arg-Lys-Ala-Arg-Arg-Gln-Ala-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu YARKARRQARRTALDWSWLQTE (SEQ ID NO:137), D-Tyr-D-Ala-D-Arg-D-Lys-D-Ala-D-Arg-D-Arg-D-Gln-D-Ala-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu yarkarrqrrrTALDWSWLQTE (SEQ ID NO:138), Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu YARAARRAARRTALDWSWLQTE (SEQ ID NO:139), D-Tyr-D-Ala-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-D-Ala-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu yaraarraarrTALDWSWLQTE (SEQ ID NO:140), Tyr-Gly-Arg-Lys-Lys-Arg-Gln-Arg-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu YGRKKRRQRRRLDWSWL (SEQ ID NO:141), D-Tyr-D-Gly-D-Arg-D-Lys-D-Lys-D-Arg-D-Gln-D-Arg-D-Arg-D-Arg-Leu-Asp-Trp-Ser-Trp-Leu ygrkkrrqrrrLDWSWL (SEQ ID NO:142), Arg-Arg-Met-Lys-Trp-Lys-Lys-Leu-Asp-Trp-Ser-

Trp-Leu RRMKWKKLDWSWL (SEQ ID NO:143), D-Arg-D-Arg-D-Met-D-Lys-D-Trp-D-  
Lys-D-Lys-Leu-Asp-Trp-Ser-Trp-Leu rrmkwkkLDWSWL (SEQ ID NO:144), D-Arg-D-Arg-  
D-Arg-D-Arg-D-Arg-D-Arg-Leu-Asp-Trp-Ser-Trp-Leu rrrrrrLDWSWL (SEQ ID  
NO:145), Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu  
YARAARRAARRLDWSWL (SEQ ID NO:146), D-Tyr-D-Ala-D-Arg-D-Ala-D-Ala-D-Arg-D-  
Arg-D-Ala-D-Ala-D-Arg-D-Arg-Leu-Asp-Trp-Ser-Trp-Leu yaraarraarrLDWSWL (SEQ ID  
NO:147), and Arg-Arg-Arg-Arg-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu  
RRRRRRRLDWSWL (SEQ ID NO:148).

13. (Currently Amended) An anti-inflammatory compound comprising an amino acid sequence selected from the group consisting of

H-Arg-Arg-Met-Lys-Trp-Lys-Lys-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu-NH<sub>2</sub>  
H-RRMKWKKTALDWSWLQTE NH<sub>2</sub> (SEQ ID NO: 161);  
H-Tyr-Gly-Arg-Lys-Lys-Arg-Gln-Arg-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-  
Gln-Thr-Glu-NH<sub>2</sub> H-YGRKKRRQRRRTALDWSWLQTE NH<sub>2</sub> (SEQ ID NO: 162);  
H-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Thr-Ala-Leu-Asp-Trp-Ser-  
Trp-Leu-Gln-Thr-Glu-NH<sub>2</sub> H-rrrrrrTALDWSWLQTE NH<sub>2</sub> (SEQ ID NO: 163);  
H-Tyr-Ala-Arg-Lys-Ala-Arg-Arg-Gln-Ala-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-  
Trp-Leu-Gln-Thr-Glu-NH<sub>2</sub> H-YARKARROARRTALDWSWLQTE NH<sub>2</sub> (SEQ ID NO: 164);  
H-Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-  
Trp-Leu-Gln-Thr-Glu-NH<sub>2</sub> H-YARAARRAARRTALDWSWLQTE NH<sub>2</sub> (SEQ ID NO: 165);  
H-Arg-Arg-Met-Lys-Trp-Lys-Lys-Leu-Asp-Trp-Ser-Trp-Leu-NH<sub>2</sub> H-  
RRMKWKKLDWSWL NH<sub>2</sub> (SEQ ID NO: 166);  
H-D-Arg-D-Arg-D-Met-D-Trp-D-Lys-D-Lys-Leu-Asp-Trp-Ser-Trp-Leu-  
NH<sub>2</sub> H-rrmkwkkLDWSWL NH<sub>2</sub> (SEQ ID NO: 167);  
H-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Leu-Asp-Trp-Ser-Trp-Leu-  
NH<sub>2</sub> H-rrrrrrLDWSWL NH<sub>2</sub> (SEQ ID NO: 168);  
H-Tyr-Ala-Arg-Ala-Ala-Arg-Arg-Ala-Ala-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu-  
NH<sub>2</sub> H-YARAARRAARRLDWSWL NH<sub>2</sub> (SEQ ID NO: 169);  
H-D-Tyr-D-Ala-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-D-Ala-D-Ala-D-Arg-D-Arg-  
Leu-Asp-Trp-Ser-Trp-Leu-NH<sub>2</sub> H-yaraarraarrLDWSWL NH<sub>2</sub> (SEQ ID NO: 170); and  
H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Leu-Asp-Trp-Ser-Trp-Leu-  
NH<sub>2</sub> H-YGRKKRRQRRRLDWSWL NH<sub>2</sub> (SEQ ID NO: 171).